Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia

Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.